Connect with us

Technology

Discovery Life Sciences Announces Upcoming Launch of Tumoroids at Precision Med Tri-Con in San Diego

Published

on

Global Biospecimen Leader to Unveil Transformative Tool for Oncology Studies

HUNTSVILLE, Ala., Feb. 25, 2025 /PRNewswire/ — Discovery Life Sciences (Discovery), a global leader in biospecimen solutions and specialty lab services, announced today that it will launch a new product to help advance oncology research, Tumoroid Cell Lines, OncoPro™ Medium-Derived, at  Precision Med Tri-Con 2025, March 11-13 in San Diego, California. 

To learn about Discovery’s new tumoroid cell lines, which are derived and expanded in Thermo Fisher Scientific’s Gibco™ OncoPro™ Tumoroid Culture Medium, click here.

“Our tumoroid cell lines are a transformative tool that can help eliminate major barriers to oncology research, giving scientists a powerful, predictive tool to identify life-changing therapies faster,” said McLean Collins, Discovery’s president of Biospecimens Products & Services. “This product also represents Discovery’s continued commitment to driving innovation in cancer research and complements our cell biology offerings in CFC and ADC assays along with our 10X single cell portfolio.”

Tumoroid Cell Lines, OncoPro™ Medium-Derived are patient-derived cancer cells that are cultivated as 3D, self-organized multicellular structures, serving as highly predictive tools for drug and diagnostic development and offering greater biological relevance compared to traditional 2D cancer models.

Tri-Con 2025 Highlights

In addition to unveiling its tumoroid cell lines, Discovery will feature scientific engagements at Tri-Con led by Dr. Shawn Fahl, vice president, Lab Operations, Cell Services & R&D, Biospecimens, including:

Luncheon presentation titled From Biorepository to Breakthroughs: Accelerating Development with Spatial and Transcriptomic Analyses as part of the Spatial Biology and Single-Cell Multiomics program on March 11.

Keynote panel discussion on Tech Trends in Precision Medicine in which Dr. Fahl will share his insights on emerging innovations in precision medicine on March 12.

Poster presentation titled Cell-Free DNA and Beyond: A Comprehensive Evaluation of Liquid Biopsy Workflows Across a Global Clinical Biorepository

“We will be showcasing several exciting studies at Precision Med Tri-Con this year, highlighting our dedication to advancing precision medicine by integrating advanced technologies and high-quality biospecimens into our workflows,” said Dr. Fahl. “We look forward to engaging with the scientific community and exploring new ways to shape the future of oncology research together.”

Discovery’s strategic investments in advanced technologies, including AI-powered pathology and retrospective clinical biomarker testing workflows, empower its customers with actionable, quantitative insights from biospecimens. For more information about Discovery’s products and services, visit www.dls.com.

Note:  Gibco™ and OncoPro™ are trademarks of Thermo Fisher Scientific and its subsidiaries.  The products are for Research Use Only, not for use in diagnostic procedures.

About Discovery Life Sciences  

Discovery Life Sciences is a global leader in biospecimens and specialty lab services, enabling the discovery and development of therapeutics and diagnostics that improve patient outcomes. Our extensive portfolio of biospecimens, cellular starting materials, and preclinical ADME-tox solutions accelerates research with reliable, high-quality products and expertise. Through our comprehensive suite of specialty lab services in genomics, proteomics, cell biology, and molecular pathology, we deliver critical data and insights for biomarker discovery and both retrospective and prospective clinical trials. With a vision to be the most trusted partner in life science research and clinical development, Discovery Life Sciences is committed to advancing life sciences and transforming lives. Visit www.dls.com for more information. 

Discovery Life Sciences Media 

Todd Poley
Chief Marketing Officer
+1 256 505 1578
todd.poley@dls.com 

Photo – https://mma.prnewswire.com/media/2626243/Discovery_Life_Sciences__Tumoroid.jpg
Logo – https://mma.prnewswire.com/media/2626244/Discovery_Life_Sciences__Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/discovery-life-sciences-announces-upcoming-launch-of-tumoroids-at-precision-med-tri-con-in-san-diego-302383907.html

Continue Reading

Technology

MiniTool ShadowMaker 5.0 Introduces Cloud Sync for Google Drive and OneDrive

Published

on

By

VANCOUVER, BC, Oct. 22, 2026 /PRNewswire/ — MiniTool® Software Limited has announced the release of MiniTool ShadowMaker 5.0, the latest version of its Windows backup and file sync software. The update introduces a new Cloud Sync feature for Google Drive and OneDrive, along with enhancements to the registration and purchase experience, interface refinements, and compatibility fixes.

New Features and Improvements in MiniTool ShadowMaker 5.0

1. Cloud Sync to Google Drive and OneDrive

MiniTool ShadowMaker 5.0 introduces Cloud Sync, allowing users to synchronize files and folders from a Windows computer to Google Drive or OneDrive. Users can choose the files and folders they want to sync and select their preferred cloud storage service as the destination.

The new feature supports one-way synchronization from a local Windows PC to cloud storage, providing an additional way to save copies of important files outside of your computer. Together with MiniTool ShadowMaker’s existing local file sync function, Cloud Sync expands the available destinations for file sync.

2. Streamlined License & Plan Management

The latest update introduces an enhanced register interface that remains easily accessible even after activation. Registered users can now effortlessly review their current plan, explore upgrade options, or update their license key anytime for a smoother user experience.

These refinements are intended to improve usability when users manage their software registration and licensing.

3. Interface Refinements and Compatibility Fixes

MiniTool ShadowMaker 5.0 includes interface improvements and fixes for certain display issues. One notable fix addresses a blurry display issue that could occur on some systems equipped with AMD GPUs.

These changes focus on resolving specific issues and improving the user experience on affected systems.

4. Additional Improvements

Beyond Cloud Sync and the changes outlined above, MiniTool ShadowMaker 5.0 includes additional interface and functionality refinements. Together, these updates further improve the software’s usability while expanding its file synchronization options.

With support for Google Drive and OneDrive, MiniTool ShadowMaker 5.0 provides Windows users with another approach to manage file copies across local and cloud storage. Users who want to synchronize files to cloud storage can download the Free Edition and explore the new capabilities.

About MiniTool ShadowMaker

MiniTool ShadowMaker is a Windows backup and file sync solution designed to help users protect their operating systems and important data. It supports backing up Windows systems, disks, partitions, files, and folders to local drives, external hard drives, shared folders, and other supported locations. Users can select specific items to back up according to their needs.

For users who need to migrate data to another drive, MiniTool ShadowMaker offers a disk cloning feature. The software also supports restoring backed-up data and creating bootable media for system recovery.

By combining backup, file synchronization, disk cloning, and restore capabilities, MiniTool ShadowMaker offers Windows users a set of tools for data protection and system recovery.

About MiniTool® Software Limited

MiniTool Software Limited is a professional software company that develops computer applications. It provides software for partition management, data recovery, data backup and sync, video editing, multimedia conversion, and screen recording for home and business users. The company is committed to developing innovative, reliable, and easy-to-use software that simplifies everyday digital tasks.

View original content to download multimedia:https://www.prnewswire.com/news-releases/minitool-shadowmaker-5-0-introduces-cloud-sync-for-google-drive-and-onedrive-302916663.html

SOURCE MiniTool® Software Limited

Continue Reading

Technology

Rocket Companies to Announce Third Quarter 2026 Results on October 29, 2026

Published

on

By

DETROIT, Oct. 22, 2026 /PRNewswire/ — Rocket Companies, Inc. (NYSE: RKT) (“Rocket Companies” or “the Company”), the Detroit-based homeownership platform, today announced that the Company will issue its third quarter 2026 earnings on October 29, 2026. Leadership will host a conference call to discuss results at 4:30 p.m. ET on that date. A press release detailing the Company’s results will be issued prior to the call.

A live webcast of the event will be available on the “Events & Presentations” section of the Company’s Investor Relations website at ir.rocketcompanies.com. A replay of the webcast will be available on the Investor Relations website following the event.

About Rocket Companies

Founded in 1985, Rocket Companies (NYSE: RKT) is a Detroit-based homeownership platform including mortgage, real estate and personal finance businesses: Rocket Mortgage, Redfin, Rocket Close, Rocket Money and Rocket Loans.

With insights from more than 160 million calls with clients each year, more than 30 petabytes of data and a mission to Help Everyone Home, Rocket Companies is well positioned to be the destination for AI-fueled homeownership.

For more information, please visit the Company’s Corporate website or Investor Relations website.

View original content to download multimedia:https://www.prnewswire.com/news-releases/rocket-companies-to-announce-third-quarter-2026-results-on-october-29-2026-302917496.html

SOURCE Rocket Companies, Inc.

Continue Reading

Technology

Lunai Bioworks Announces Receipt of Nasdaq Determination and Intention to Voluntarily Delist and Deregister

Published

on

By

SACRAMENTO, Calif., Oct. 22, 2026 /PRNewswire/ — Lunai Bioworks Inc. (Nasdaq: LNAI) (the “Company”) announced that on October 21, 2026, it received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company no longer complies with Nasdaq Listing Rule 5550(b)(1), which requires minimum stockholders’ equity of $2,500,000. The Company reported a stockholders’ deficit of $(9,024,946) in its Annual Report on Form 10-K for the fiscal year ended June 30, 2026, and does not meet the alternative market value of listed securities or net income standards. Because the Company is subject to a mandatory Hearings Panel Monitor under Nasdaq Listing Rule 5815(d)(4)(B), Nasdaq staff determined to delist the Company’s securities. Trading in the Company’s common stock on Nasdaq is expected to be suspended at the opening of business on October 30, 2026.

The Company will not request a hearing. Rather than contest the staff determination, the Company’s Board of Directors approved on October 22, 2026 the voluntary withdrawal of the Company’s common stock from listing on Nasdaq under Rule 12d2-2(c) under the Securities Exchange Act of 1934, as amended. The Board took this action because of the staff determination and the Company’s financial condition, and concluded that the cost of continued listing and SEC reporting is not justified.

The Company notified Nasdaq of its intention on October 22, 2026. The Company intends to file a Form 25 with the Securities and Exchange Commission (the “SEC”) on or about November 2, 2026, and expects the delisting to become effective on or about November 12, 2026. The Company then intends to file a Form 15 to suspend its SEC reporting obligations, to the extent it is eligible to do so. The Company’s SEC reporting obligations will continue unless and until they are terminated or suspended in accordance with the SEC’s rules.

The Company does not intend to arrange for quotation of its common stock on any over-the-counter market and cannot assure that any trading market for its common stock will exist after trading on Nasdaq is suspended.

Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the expected suspension of trading, the expected timing of the Form 25 and Form 15 filings, and the expected timing of delisting and deregistration. Actual results may differ materially due to risks and uncertainties, including Nasdaq and SEC procedures and the Company’s financial condition. The Company undertakes no obligation to update these statements, except as required by law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lunai-bioworks-announces-receipt-of-nasdaq-determination-and-intention-to-voluntarily-delist-and-deregister-302917510.html

SOURCE Lunai Bioworks Inc.

Continue Reading

Trending